Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment

References

• Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. (1999). A novel human xenograft model of inflammatory breast cancer. Cancer Res, 59, 5079–5084.
   PubMedGoogle Scholar
• Canales BK, Li Y, Thompson MG, Gleason JM, Chen Z, Malaeb B, Corey DR, Herbert BS, Shay JW, Koeneman KS. (2006). Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urol Oncol, 24, 141–151.
   Google Scholar
• Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D’Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M. (2005). HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer, 93, 7–14.
   PubMed Web of Science ®Google Scholar
• Fujii T, Yokoyama G, Takahashi H, Toh U, Kage M, Ono M, Shirouzu K, Kuwano M. (2008). Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer, 15, 73–78.
   Google Scholar
• Gao P, Zhou GY, Lei DP, Zhang XF, Li L, Xu JW, Lin XY. (2007). Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Cytotherapy, 9, 795–801.
   Web of Science ®Google Scholar
• Gralow JR. (2006). Breast cancer 2004: Progress and promise on the clinical front. Phys Med, 21 (Suppl 1), 2.
   Google Scholar
• Hatake K, Tokudome N, Ito Y. (2007). Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. Breast Cancer, 14, 132–149.
   Google Scholar
• Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH. (2007). Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Oligonucleotides, 17, 201–212.
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. (2002). Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol, 20, 1467–1472.
   PubMed Web of Science ®Google Scholar
• Miles DW. (2001). Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting. Breast Cancer Res, 3, 380–384.
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, Sarkar FH. (2005). Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas, 31, 317–324.
   PubMed Web of Science ®Google Scholar
• Moulder S, Hortobagyi GN. (2008). Advances in the treatment of breast cancer. Clin Pharmacol Ther, 83, 26–36.
   PubMed Web of Science ®Google Scholar
• Orlando L, Colleoni M, Fedele P, Cusmai A, Rizzo P, D’Amico M, Chetri MC, Cinieri S. (2007). Management of advanced breast cancer. Ann Oncol, 18 (Suppl 6), vi74–vi76.
   Google Scholar
• Pirollo KF, Rait A, Sleer LS, Chang EH. (2003). Antisense therapeutics: From theory to clinical practice. Pharmacol Ther, 99, 55–77.
   PubMed Web of Science ®Google Scholar
• Redell MS, Tweardy DJ. (2005). Targeting transcription factors for cancer therapy. Curr Pharm Des, 11, 2873–2887.
   PubMed Web of Science ®Google Scholar
• Roh H, Hirose CB, Boswell CB, Pippin JA, Drebin JA. (1999). Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery, 126, 413–421.
   Google Scholar
• Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. (2008). Antisense therapeutics for tumor treatment: The TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res, 177, 137–150.
   PubMedGoogle Scholar
• Sleijfer S, Seynaeve C, Wiemer E, Verweij J. (2006). Practical aspects of managing gastrointestinal stromal tumors. Clin Colorectal Cancer, 6 (Suppl 1), S18–S23.
   Google Scholar
• Song HF, Tang ZM, Yuan SJ, Zhu BZ. (2000). Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis. Acta Pharmacol Sin, 21, 80–86.
   Google Scholar
• Sun JZ, Song HF, Li LS, Song ST, Zhu JH, Zhao H. (2005). Inhibitory effect of antisense oligonucleotides targeting HER2 mRNA on proliferation of breast cancer cell line in vitro. Cancer Res Prev Treat, 32, 745–748.
   Google Scholar
• Tanaka M, Obata T, Sasaki T. (1996). Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer, 32A, 226–230.
   PubMed Web of Science ®Google Scholar
• Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. (2002). Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res, 62, 6712–6716.
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Gelmon KA, Masin D, Bally MB. (2003). Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol, 3, 261–271.
   PubMedGoogle Scholar
• Yeon CH, Pegram MD. (2005). Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs, 23, 391–409.
   PubMed Web of Science ®Google Scholar